ResearcherThe University of Texas MD Anderson Cancer CenterNo recent work listed

John F. Hancock

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0542-4710; OpenAlex author ID A5037758372. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 3

Papers, trials and grants by year

2021: 2 papers

Papers 2

Components of the phosphatidylserine endoplasmic reticulum to plasma membrane transport mechanism as targets for KRAS inhibition in pancreatic cancer. Last author DOI 10.1073/pnas.2114126118 ↗
The development of multi-kinase inhibitors as pancreatic cancer therapeutics. Last author DOI 10.1097/cad.0000000000001177 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Paul Dent · 1 shared paper, 2021 · strength 0.19
- Paper The development of multi-kinase inhibitors as pancreatic cancer therapeutics. DOI 10.1097/cad.0000000000001177 ↗
Laurence A. Booth · 1 shared paper, 2021 · strength 0.19
- Paper The development of multi-kinase inhibitors as pancreatic cancer therapeutics. DOI 10.1097/cad.0000000000001177 ↗
Walaa E. Kattan · 1 shared paper, 2021 · strength 0.14
- Paper Components of the phosphatidylserine endoplasmic reticulum to plasma membrane transport mechanism as targets for KRAS i… DOI 10.1073/pnas.2114126118 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.